People Are Legally Barred From Repeating His # MeToo JokesEric Schaal 17 July 2019 More than 50 years have passed since The Beatles recorded and released the album known as Paul McCartney which still sings ‘ Blackbird ‘ to adoring fans. Also in 2019 Ringo Starr is still alive and well (and on touring). Ringo celebrated on the occasion of his 79th birthday with his annual harmony and love-fest. The White Album reflects the reverse of that feeling for many Beatles fans-it was more like the beginning of the end. Yet Ringo doesn’t dwell on the bad moments. Talking to Parade, he remembered that the Fab Four had returned to performing the way the band had in their early days. Instead of Sgt Pepper’s The Beatles ‘ strings and flutes they struck with heavy guitars. The four band members packed into a tiny studio on John Lennon’s “Your Blues,” to get a true “real” sound on the album. Such close quarters combined with the song’s heaviness marked Ringo’s album height. ‘ Yer Blues ‘ lists Ringo as the highlight of the classic ‘ White Album. ‘
Figure 1 Jane Birkin George Harrison et Ringo Starr at the Cannes France International Film Festival in May 1968. KEYSTONE-FRANCE / Gamma-Rapho via Getty Images In an interview with Parade’s Jim Farber Ringo addressed his age (79!), his sobriety (now at 30 years of age and counting), and his All Starr Band (still playing gigs). After a friendly round of questions about current events, Farber got stuff to the Beatles beginning with The White Album’s tensions. When it came to the suggestion that the album sent out the party under, Ringo didn’t bite. “We didn’t fall apart until we split up anyway,” he said. “Till that point, we’ve played together. I love The White Album. “Ringo explicitly loved the studio’s energy. Beatles fans who saw Anthology (1995) may then recall the excitement Ringo had for the album. “Yer Blues” he said, “you can’t top it up.” “This group was together; it was really like the grunge rock of the 1960s. Grunge blues. “Ringo was frustrated by the negativity in the studio just after that song was released.
Days after ‘ Yer Blues ‘ album, Ringo got fed up and walked out on the band.
Derek HoffmanGoogle+ More Articles 31 July 2013 Genomic Health Inc. (NASDAQ: GHDX) suffered a loss and missed the expectations of Wall Street AND fell short on meeting revenue targets. Missing revenue is a negative sign for shareholders expecting high growth out of the company. Shares are 1.91 per cent lower.
Medical genomics inc. Earnings Cheat Sheet
Results: Reported earnings per share dropped to $-0.1 in the quarter from $0.06 in the quarter before. Revenue: from the previous quarter, rose 10.53 per cent to $63.7 million. Quoting Management: “We generated strong results in the second quarter with year-over-year drug revenue growth of 11 percent and test growth of 9 percent driven by higher U.S. invasive breast cancer penetration and the continued success of our international expansion,” said Kim Popovits Chairman of the Chief Executive Officer and President of Genomic Health. “Importantly, with the successful launch of Oncotype DX prostate cancer testing our third drug franchise and Medicare reimbursement for our DCIS ranking, we achieved two major milestones towards further market diversification and long-term development.”
Main Stats (on next page) …
Sales decreased 0 percent from $0 in the previous quarter. EPS rose annually to $-0.1 vs previous quarter EPS to $-0.03. Stocks with better earnings metrics merit your extra attention. It is precisely for this reason that “E = Earnings Are That Quarter-Over-Quarter” is a core component of our CHEAT SHEET investment system. Don’t waste another minute-click here now and get picks from our CHEAT SHEET portfolio. (Fundamentals of the business provided by Xignite Financials. Contact any income differences [ at ] wallstcheatsheet.com)Derek HoffmanGoogle+ More Articles 31 July 2013 Genomic Health Inc. (NASDAQ: GHDX) suffered a loss and missed the expectations of Wall Street AND fell short on meeting revenue targets. Missing revenue is a negative sign for shareholders expecting high growth out of the company. Shares are 1.91 per cent lower.
Medical genomics inc. Earnings Cheat Sheet
Results: Reported earnings per share dropped to $-0.1 in the quarter from $0.06 in the quarter before. Revenue: from the previous quarter, rose 10.53 per cent to $63.7 million. Quoting Management: “We generated strong results in the second quarter with year-over-year drug revenue growth of 11 percent and test growth of 9 percent driven by higher U.S. invasive breast cancer penetration and the continued success of our international expansion,” said Kim Popovits Chairman of the Chief Executive Officer and President of Genomic Health. “Importantly, with the successful launch of Oncotype DX prostate cancer testing our third drug franchise and Medicare reimbursement for our DCIS ranking, we achieved two major milestones towards further market diversification and long-term development.”
Main Stats (on next page) …
Sales decreased 0 percent from $0 in the previous quarter. EPS rose annually to $-0.1 vs previous quarter EPS to $-0.03. Stocks with better earnings metrics merit your extra attention. It is precisely for this reason that “E = Earnings Are That Quarter-Over-Quarter” is a core component of our CHEAT SHEET investment system. Don’t waste another minute-click here now and get picks from our CHEAT SHEET portfolio. (Fundamentals of the business provided by Xignite Financials. Contact any income differences [ at ] wallstcheatsheet.com)